Jubilant Life gains on ANDA approval for generic drug

The stock was up 3.4% at Rs 961 in intra-day trade, extending its past two days 3% gain on BSE.

Jubilant Life Sciences was up 3.4% at Rs 961, extending its 3% gain in past two days on BSE, after the company announced that it has received Abbreviated New Drug Application (ANDA) approval for Clonidine Hydrochloride Extended-Release Tablets.

“Jubilant Pharma, a material wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg, the generic version of Kapvay® of Concordia,” Jubilant Life Sciences said in a press release.

Concordia is used for the treatment of attention deficit hyperactivity disorder (ADHD) as